Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that market, according to InPharm.
The new venture, which the manufacturer says will be a separate business, is tasked with developing and commercializing Boehringer’s own biosimilars.
“We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines,” explained Wolfram Carius, member of Boehringer’s board of managing directors.
“We feel confident that we are able to leverage our capabilities in product development, supply and clinical expertise at Boehringer Ingelheim to offer high quality biosimilars understanding patients’ needs,” he added.
Biosimilars differ from generics in that they are close copies of, rather than identical to, off-patent biologic brands.